Satellite Symposia
SATELLITE SYMPOSIA
nAMD Treatment Fundamentals: Keys to a Proactive and Individualized Anti-VEGF Treatment Approach for nAMD Patients
9 September, 14:00 CEST
Chairperson(s): A. Loewenstein ISRAEL & N. Eter GERMANY
Details
nAMD Treatment Fundamentals: Keys to a Proactive and Individualized Anti-VEGF Treatment Approach for nAMD Patients
Chairperson(s): A. Loewenstein ISRAEL & N. Eter GERMANY
Speakers and presentations:
A. Loewenstein ISRAEL
14:00 Welcome & ARS
N. Eter GERMANY
14:02 Review of EURETINA nAMD clinical trends survey data
S. Waldstein AUSTRIA
14:07 Diagnostic imaging and how to track nAMD disease progression with current technology
V. Chaudhary CANADA
14:16 Updates to Anti-VEGF treatment dosing and duration – impact on treatment protocols
J.F Korobelnik FRANCE
14:25 Balancing visual outcome goals vs. diagnostic outcome data – what’s the more important metric?
A. Loewenstein ISRAEL
14:34 Final ARS, live Q&A and panel discussion
14:45 End of Session
Beyond VEGF: Targeting the Ang-Tie Pathway for the Management of Retinal Diseases
9 September, 18:45 CEST
Chairperson(s): P. Schlottmann ARGENTINA
Details
Beyond VEGF: Targeting the Ang-Tie Pathway for the Management of Retinal Diseases
Chairperson(s): P. Schlottmann ARGENTINA
Speakers and presentations:
P. Schlottmann ARGENTINA | A. Joussen GERMANY | J. Monés SPAIN
18:45 Impact of anti-VEGF therapies and future perspectives; Advancing our understanding of the angiopoietin pathway; Targeting the Ang-Tie pathway; Phase 3 clinical evidence; Anti-inflammatory and anti-fibrotic effects of dual Ang-2/VEGF-A inhibition
P. Schlottmann ARGENTINA | A. Joussen GERMANY | J. Monés SPAIN
19:30 Live Q&A
19:45 End of Session
The Big Picture in Clinical Practice
10 September, 11:00 CEST
Chairperson(s): A. Loewenstein ISRAEL
Details
The Big Picture in Clinical Practice
Chairperson(s): A. Loewenstein ISRAEL
Speakers and presentations:
A. Loewenstein ISRAEL
11:00 Welcome & Introduction
L. Kodjikian FRANCE
11:05 Consensus papers on the use of a corticosteroid in DME and the Delphi approach
J. Zarranz-Ventura SPAIN
11:25 Suitable naïve versus pre-treated DME patients
A. Loewenstein ISRAEL
11:35 Q&A
11:45 End of Session
Clinical Perspectives on nAMD Management: Making Informed Decisions Along the Patient Journey
10 September, 11:00 CEST
Chairperson(s): A. Koh SINGAPORE
Details
Clinical Perspectives on nAMD Management: Making Informed Decisions Along the Patient Journey
Chairperson(s): A. Koh SINGAPORE
Speakers and presentations:
A. Koh SINGAPORE
11:00 Welcome and introduction to nAMD
R. Khoramnia GERMANY
11:05 Managing my nAMD patients: making informed decisions at therapy initiation
A. Khanani USA
11:15 Managing nAMD: making informed decisions along the patient journey
All Faculty
11:30 Q&A
A. Koh SINGAPORE
11:40 Concluding remarks
11:45 Session Ends
Exploring New Retina Technologies and Beyond
10 September, 11:00 CEST
Chairperson(s): C. Mateo SPAIN
Details
Exploring New Retina Technologies and Beyond
Chairperson(s): C. Mateo SPAIN
Speakers and presentations:
A. Chandra UK
11:00 Bi-Blade™ and bimanual surgery
Y. Le Mer FRANCE
11:10 Experience with the latest generation Vitesse®
B. Parolini ITALY
11:20 Management of complex cases with B+L technology
C. Mateo SPAIN
11:30 How would you do that? Panel discussion on interesting case studies
11:45 Session Ends
Restoring Vision in Advanced AMD: A Roundtable Discussion on Treatment Options
10 September, 11:00 CEST
Chairperson(s): J. Talamo USA
Details
Restoring Vision in Advanced AMD: A Roundtable Discussion on Treatment Options
Chairperson(s): J. Talamo USA
Speakers and presentations:
D. Keegan Ireland
11:00 Overview of treatment options
A. Augustin Germany
11:05 Discussion
W. Sekundo Germany
11:05 Discussion
J. Silvestri Ireland
11:05 Discussion
11:45 Session Ends
A Pathway to Enhanced Care for Inherited Retinal Dystrophy Patients
10 September, 14:00 CEST
Chairperson(s): B.P. Leroy BELGIUM
Details
A Pathway to Enhanced Care for Inherited Retinal Dystrophy Patients
Chairperson(s): B.P. Leroy BELGIUM
Speakers and presentations:
14:00 Alessia’s story
B.P. Leroy BELGIUM
14:03 Welcome and introduction perspective
N. Oluonye UK
14:06 The child behind the eye
C. Boon THE NETHERLANDS
14:08 Redefining the standard of care for pediatric and adult IRD patients
M. Moosajee UK
14:16 A multidisciplinary approach to diagnosing and treating IRDs
R. Ba-Abbad SAUDI ARABIA
14:24 Unlocking the IRD genetic code
K. Klemp DENMARK
14:32 The treatment experience: a vitreoretinal surgeon’s perspective
All Faculty
14:35 The importance of ongoing patient follow-up
B.P. Leroy BELGIUM
14:43 Summary and close
11:45 Session Ends
The Ophthalmology Clinic of 2030: What is on the Horizon?
10 September, 14:00 CEST
Chairperson(s): M. de Smet SWITZERLAND
Details
The Ophthalmology Clinic of 2030: What is on the Horizon?
Chairperson(s): M. de Smet SWITERLAND
Speakers and presentations:
A. Loewenstein ISREAL
14:00 Can we have an ophthalmology clinic at home?
H. Bogunović AUSTRIA
14:06 How can AI help us and our patients?
P. Lanzetta ITALY
14:12 How can we optimize our existing treatments? & Can we treat at home?
M. Pennesi USA
14:24 How can we treat the uncurable?
P. Bussfeld SWITZERLAND/ GERMANY
14:34 What is Bayer’s role in the future of ophthalmology?
11:45 Session Ends
AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics
10 September, 14:00 CEST
Chairperson(s): A. Loewenstein ISRAEL
Details
AMD and DME Treatment Innovations: Home Monitoring, Artificial Intelligence Diagnostics and Extended Duration Anti-VEGF Therapeutics
Chairperson(s): A. Loewenstein ISREAL
Speakers and presentations:
A. Loewenstein ISREAL
14:00 Welcome, ARS & review of EURETINA AMD & DME clinical trends survey data
S. Wolf SWITZERLAND
14:05 The Anti-VEGF treatment burden
R. Tadayoni FRANCE
14:13 Current and future applications of longer lasting Anti-VEGF therapeutics
C. Awh USA
14:21 Insights and pearls on implantable sustained release technologies
A. Loewenstein ISREAL
14:29 Artificial Intelligence (AI) in nAMD & DME treatment decision-making
A. Loewenstein ISREAL
14:37 Final ARS, live Q&A and panel discussion
14:45 Session Ends
DME Management: Challenges and Opportunities
10 September, 18:00 CEST
Chairperson(s): T. Wong SINGAPORE
Details
DME Management: Challenges and Opportunities
Chairperson(s): T. Wong SINGAPORE
Speakers and presentations:
T. Wong SINGAPORE
18:00 Welcome and introduction
C. Creuzot-Garcher FRANCE
18:05 Unmet needs and challenges and opportunities in the current management of DME
N. Eter GERMANY
18:15 Why fluid matters in DME
C. Wykoff USA
18:25 Latest evidence from an advanced clinical development program perspective
T. Wong SINGAPORE
18:40 Summary
All Faculty
18:45 Live discussion with Q&A
T. Wong SINGAPORE
18:59 Meeting close
19:00 Session Ends
Geographic Atrophy: What Have we Learnt and What is Still to be Discovered?
10 September, 18:00 CEST
Chairperson(s): F.G. Holz GERMANY
Details
Geographic Atrophy: What Have we Learnt and What is Still to be Discovered?
Chairperson(s): F.G. Holz GERMANY
Speakers and presentations:
F.G. Holz GERMANY
18:00 Introduction
R. Tadayoni FRANCE
18:03 Expanding our knowledge in GA
All Faculty
18:13 Live Panel Discussion
F.G. Holz GERMANY
18:18 Emerging clinical data in GA
All Faculty
18:28 Live Panel Discussion
J. Monés SPAIN
18:33 Continued evolution of our understanding of AMD and the role of new vessels
All Faculty
18:43 Live Panel Discussion
F.G. Holz GERMANY
18:48 Summary and close
18:50 Session Ends
Optimising nAMD Management Through Longer-acting Therapies
10 September, 18:00 CEST
Chairperson(s): A. Laidlaw UK
Details
Optimising nAMD Management Through Longer-acting Therapies
Chairperson(s):A. Laidlaw UK
Speakers and presentations:
A. Laidlaw UK
18:00 Welcome and opening remarks
A. Laidlaw UK
18:01 Addressing the unmet need for longer-acting therapies for nAMD
N. Holekamp USA
18:09 Continuous delivery of anti–VEGF-A
A. Laidlaw UK
18:19 Summary
A. Laidlaw UK & N. HolekampUSA
18:20 - 18:40 Panel Discussion
18:40 Session Ends
Looking into the Future: nAMD Detection and Progression
10 September, 18:00 CEST
Chairperson(s): A. Loewenstein ISRAEL
Details
Looking into the Future: nAMD Detection and Progression
Chairperson(s): A. Loewenstein ISREAL
Speakers and presentations:
N. Bressler USA
18:00 Looking into the future: predicting progression in nAMD
A. Loewenstein ISREAL
18:11 Looking into the future: remote monitoring
S. Sadda USA
18:22 Looking into the future: imaging in nAMD
18:50 Session Ends
Controversies in Laser Treatments in 2021
10 September, 18:00 CEST
Chairperson(s): P. Stanga UK
Details
Controversies in Laser Treatments in 2021
Chairperson(s): P. Stanga UK
Speakers and presentations:
V. Chong UK
18:00 Macular laser photocoagulation: still relevant in 2021?
L. Wu COSTA RICA
18:15 Anti-VEGF vs Laser for PDR, a changing treatment paradigm?
P. Stanga UK
18:30 Diagnosis, classification and management options for vitreous opacities
18:50 Session Ends
Digital Innovations: Jumping from Concepts to the Clinic
11 September, 11:00 CEST
Chairperson(s): N. Bressler USA
Details
Digital Innovations: Jumping from Concepts to the Clinic
Chairperson(s): N. Bressler USA
Speakers and presentations:
N. Bressler USA
11:00 Welcome and Open
A. Loewenstein ISRAEL
11:05 Clinical endpoint collection outside of the office
P. Keane UK
11:15 Artificial intelligence: why hasn’t it jumped to the clinic yet?
All Faculty
11:25 Panel discussion and Q&A
N. Bressler USA
11:40 Summary and close
11:45 End of Session
Maximizing Treatment Benefits for our Patients with Retinal Vascular Diseases
11 September, 11:00 CEST
Chairperson(s): J. Kitchens USA
Details
Maximizing Treatment Benefits for our Patients with Retinal Vascular Diseases
Chairperson(s): J. Kitchens USA
Speakers and presentations:
V. Chaudhary CANADA
11:00 Maximizing vision outcomes in DME: is baseline VA only one piece of the puzzle?
J. Garweg SWITZERLAND
11:10 Durability that lasts: proactive, extended dosing in retinal vascular disease
A. Chang AUSTRALIA
11:20 Aflibercept in the real-world: what’s the bigger picture?
T. Langmann GERMANY
11:27 Understanding the target: what are we aiming for?
11:35 End of Session
Evolution in Surgical Techniques - The Modern VR Procedure
11 September, 11:00 CEST
Chairperson(s): R. Tadayoni FRANCE
Details
Evolution in Surgical Techniques - The Modern VR Procedure
Chairperson(s): R. Tadayoni FRANCE
Speakers and presentations:
R. Tadayoni FRANCE
11:00 Welcome and introduction to nAMD
D. Chow CANADA
11:01 The shovel and cut technique: management of complex diabetic retinopathy in 25G surgery
S. Rizzo ITALY
11:15 Speed and stability: rethinking 27G surgery
R. Tadayoni FRANCE
11:29 Panel Discussion
B. Delas SPAIN
11:29 Panel Discussion
F. Barca ITALY
11:29 Panel Discussion
T. Ivonova UK
11:29 Panel Discussion
11:35 End of Session
Best-informed Decision Making – Latest Innovations in Retinal Imaging and Surgical Visualization
11 September, 11:00 CEST
Chairperson(s): J.F Korobelnik FRANCE
Details
Best-informed Decision Making – Latest Innovations in Retinal Imaging and Surgical Visualization
Chairperson(s): J.F. Korobelnik FRANCE
Speakers and presentations:
J.F. Korobelnik FRANCE
11:00 Advancements in multi-modal imaging
R. Tadayoni FRANCE
11:07 Visualization from multi-modal imaging in the clinic to 3D in the OR
L-O Hattenbach GERMANY
11:19 Changing paradigms - real-time OCT guided approaches to vitreoretinal surgery
All Faculty
11:26 Panel Discussion
11:45 End of Session
Managing Patients with Diabetic Macular Edema Through the Pandemic and Beyond: Discussing Ongoing Strategies
11 September, 14:00 CEST
Chairperson(s): R. Tadayoni FRANCE
Details
Managing Patients with Diabetic Macular Edema Through the Pandemic and Beyond: Discussing Ongoing Strategies
Chairperson(s): R. Tadayoni FRANCE
Speakers and presentations:
R. Tadayoni FRANCE
11:00 Welcome and introduction
R. Tadayoni FRANCE
11:03 Managing DME: understanding the challenges | DME and COVID-19: what have we learnt? | What will last beyond the pandemic: ongoing strategies
S. Sivaprasad UK
11:03 Managing DME: understanding the challenges | DME and COVID-19: what have we learnt? | What will last beyond the pandemic: ongoing strategies
P. Schlottmann ARGENTINA
11:03 Managing DME: understanding the challenges | DME and COVID-19: what have we learnt? | What will last beyond the pandemic: ongoing strategies
All Faculty
14:27 Panel discussion: Q&A
R. Tadayoni FRANCE
14:42Summary and close
End of Session
Flexibility and Long-term Predictability: Unlocking the Potential of Q16 Dosing for your Patients
11 September, 14:00 CEST
Chairperson(s): D. Wong CANADA
Details
Flexibility and Long-term Predictability: Unlocking the Potential of Q16 Dosing for your Patients
Chairperson(s): D. Wong CANADA
Speakers and presentations:
N. Holekamp USA
14:00 Fluid in nAMD: a pragmatic approach
J. Zarranz-Ventura SPAIN
14:10 Maintaining function with flexible treatment intervals up to Q16
TBC
14:20 Not just a case study: real-world outcomes with aflibercept
M. Stewart USA
14:28 Making sense of molecular properties
End of Session
Amgen: Spotlight on Real-world Considerations for Biosimilars in Ophthalmology
11 September, 14:00 CEST
Chairperson(s): J. Franklin USA
Details
Amgen: Spotlight on Real-world Considerations for Biosimilars in Ophthalmology
Chairperson(s): J. Franklin USA
Speakers and presentations:
J. Franklin USA
14:00 Spotlight on real-world considerations for biosimilars in ophthalmology
D. Sarraf USA
14:00 Spotlight on real-world considerations for biosimilars in ophthalmology
J. Franklin USA
14:30 Q&A
D. Sarraf USA
14:30 Q&A
14:45 End of Session
AMD Fluid Resolution: Optimizing Real-world Outcomes in nAMD Treatment
11 September, 18:15 CEST
Chairperson(s): F.G. Holz GERMANY
Details
AMD Fluid Resolution: Optimizing Real-world Outcomes in nAMD Treatment
Chairperson(s): F.G. Holz GERMANY
Speakers and presentations:
F.G. Holz GERMANY
18:15 Welcome, ARS and review of EURETINA AMD clinical trends survey data
S. Wolf SWITZERLAND
18:20 Best practices for diagnosing & monitoring AMD
N. Eter GERMANY
18:30 nAMD patient selection and outcome goals for Anti-VEGF treatment
R. Tadayoni FRANCE
18:40 nAMD treatment protocols and therapy decisions
R. Singh USA
18:50 Real-world experience with new Anti-VEGFs
F.G. Holz GERMANY
19:00 Final ARS & panel discussion
19:15 End of Session
